Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 study)

Susan H. Eshleman, Graziella Becker-Pergola, Martin Deseyve, Laura A. Guay, Martin Mracna, Thomas Fleming, Shawn Cunningham, Philippa Musoke, Francis Mmiro, J. Brooks Jackson

Research output: Contribution to journalArticlepeer-review

79 Scopus citations

Abstract

In Uganda, the HIV Network for Prevention Trials (HIVNET) 012 study recently demonstrated that single-dose nevirapine (Nvp) prophylaxis is effective for preventing mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1). This exploratory study examines the relationship between HIV-1 subtype, MTCT, and the development of Nvp resistance (NvpR) in women enrolled in HIVNET 012. For 102 women (32 whose infants were HIV-1 infected by age 6-8 weeks and 70 whose infants were uninfected), HIV-1 subtypes included 50 (49%) subtype A, 35 (34%) subtype D, 4 (4%) subtype C, 12 (12%) recombinant subtype, and 1 unclassified. There was no apparent difference in the rate of MTCT among women with subtype A versus D (adjusted odds ratio [OR], 1.24; 95% confidence interval [CI], 0.45-3.43). NvpR mutations were detected more frequently at 6-8 weeks postpartum in women with subtype D than in women with subtype A (adjusted OR, 4.94; 95% CI, 1.21-20.22). Additional studies are needed to further define the relationship between HIV-1 subtype and NvpR among women receiving Nvp prophylaxis.

Original languageEnglish (US)
Pages (from-to)914-917
Number of pages4
JournalJournal of Infectious Diseases
Volume184
Issue number7
DOIs
StatePublished - Oct 1 2001
Externally publishedYes

Bibliographical note

Funding Information:
Financial support: Elizabeth Glaser Pediatric AIDS Foundation; HIV Network for Prevention Trials, sponsored by the National Institute of Allergy and Infectious Disease (NIAID), the National Institutes of Health (NIH), and the Department of Health and Human Services (DHHS), through contracts with Family Health International (NOI-AI-35173), the Fred Hutchinson Cancer Research Center (NOI-AI-45200), and Johns Hopkins University and Makerere University (NOI-AI-35173-417); HIV Prevention Trials Network, sponsored by the NIAID, the National Institutes of Child Health and Human Development (NICH/HD), the National Institute on Drug Abuse, the National Institute of Mental Health, the Office of AIDS Research of the NIH, and the DHHS (U01-AI-46745 and U01-AI-48054); NIAID (Pediatric and Adult AIDS Clinical Trials Groups); NICH/HD (R29 34348); Applied Biosystems (reagents for human immunodeficiency virus genotyping).

Fingerprint

Dive into the research topics of 'Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 study)'. Together they form a unique fingerprint.

Cite this